Alice Sýkorová

Alice Sýkorová

Auto-generated profile, based on publicly available information

Alice Sýkorová

Charles University and University Hospital Hradec Králové

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JPJana Pospiskova
Jana Pospiskova
LSLukas Smolej
Lukas Smolej
DBDavid Belada
David Belada
MŠMartin Šimkovič
Martin Šimkovič
MMMonika Motyckova
Monika Motyckova
PZPavel Zak
Pavel Zak
Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. Conservative treatment lead to a decline of chylothorax after mean of 66 days and consisted of the treatment of the underlying disease and of simultaneous long-term supportive care (drainage of the thoracic cavity, dietary measures and nutrition management). In most cases (80%), chylothorax disappeared only after a successful therapeutic response of the underlying disease. Low-dose radiotherapy had very good effects in two patients. Conservative treatment of malignant chylothorax can be considered a suitable method. Based on our results, successful treatment of the lymphoproliferative disorder seems to be a very important factor for the disappearance of chylothorax.

18 January 2021 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
MHMartin Hutchings
Martin Hutchings
JRJohn Radford
John Radford
SAStephen Ansell
Stephen Ansell
Árpád IllésÁrpád Illés
Árpád Illés
ASAnna Sureda
Anna Sureda
Andrea GallaminiAndrea Gallamini
Andrea Gallamini
Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4–7, enrolled in the ECHELON‐1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first‐line therapy after a median follow‐up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4–7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537–0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4–7 (HR, 0.588; 95% CI, 0.386–0.894; p = 0.012). The most common adverse events (AEs) in A + AVD‐treated versus ABVD‐treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4–7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high‐risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON‐1 shows a favorable benefit‐risk balance in high‐risk patients.

1 March 2020 in Leukemia Research
Verified
Journal Article
Closed access
ASA. Sykorova
A. Sykorova
HMH. Mocikova
H. Mocikova
MLM. Lukasova
M. Lukasova
JKJ. Koren
J. Koren
PSP. Stepankova
P. Stepankova
JMJ. Markova
J. Markova

25 October 2025
Verified
Book Chapter
Closed access
PDF file
MJMiroslava Jandová
Miroslava Jandová
MLMiriam Lánská
Miriam Lánská
ASAlice Sýkorová
Alice Sýkorová
JGJiří Gregor
Jiří Gregor
PRPetra Rozsívalová
Petra Rozsívalová
BFBarry Fuller
Barry Fuller

9 September 2024 in Cancer Medicine
Verified
Journal Article
Open access
ASAlice Sýkorová
Alice Sýkorová
FFFrantišek Folber
František Folber
KPKamila Polgárová
Kamila Polgárová
HMHeidi Móciková
Heidi Móciková
JĎJuraj Ďuraš
Juraj Ďuraš
RPRobert Pytlík
Robert Pytlík
Aim: The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the risk factors for rapid progression and further treatment.Methods: We analysed 107 patients with LBCL from the Czech Republic and Slovakia who were treated in ≥3rd‐line with tisagenlecleucel or axicabtagene ciloleucel between 2019 and 2022.Results: The overall response rate (ORR) was 60%, with a 50% complete response (CR) rate. The median progression‐free survival (PFS) and overall survival (OS) were 4.3 and 26.4 months, respectively. Sixty‐three patients (59%) were refractory or relapsed after CAR‐Tx. Of these patients, 39 received radiotherapy or systemic therapy, with an ORR of 22% (CR 8%). The median follow‐up of surviving patients in whom treatment failed was 10.6 months. Several factors predicting further treatment administration and outcomes were present even before CAR‐Tx. Risk factors for not receiving further therapy after CAR‐Tx failure were high lactate dehydrogenase (LDH) levels before apheresis, extranodal involvement (EN), high ferritin levels before lymphodepletion (LD) and ECOG PS >1 at R/P. The median OS‐2 (from R/P after CAR‐Tx) was 6.7 months (6‐month 57.9%) for treated patients and 0.4 months (6‐month 4.2%) for untreated patients (p < 0.001). The median PFS‐2 (from R/P after CAR‐Tx) was 3.2 months (6‐month 28.5%) for treated patients. The risk factors for a shorter PFS‐2 (n = 39) included: CRP > limit of the normal range (LNR) before LD, albumin < LNR and ECOG PS > 1 at R/P. All these factors, together with LDH > LNR before LD and EN involvement at R/P, predicted OS‐2 for treated patients.Conclusion: Our findings allow better stratification of CAR‐Tx candidates and stress the need for a proactive approach (earlier restaging, intervention after partial remission achievement).

1 January 2022 in Neoplasma
Verified
Journal Article
Closed access
ASAlice Sýkorová
Alice Sýkorová
VPVít Procházka
Vít Procházka
HMHeidi Móciková
Heidi Móciková
AJAndrea Janíková
Andrea Janíková
RPRobert Pytlík
Robert Pytlík
MTMarek Trněný
Marek Trněný
Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index